Promising results have shown that anti-HER2 CAR-Ms not only have a multifaceted anti-tumour effect by directly killing tumour cells and by remodelling the TME, but also sensitise solid tumours to anti-PD1 immunotherapy (36). The gene discussed is ERBB2; the disease is neoplasm.